Atopix Therapeutics' Series A Round

Atopix Therapeutics raised a round of funding on October 07, 2014. Investors include SR One.

Atopix Therapeutics is a privately held clinical-stage biopharmaceutical company that is developing a class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthm…

Articles about Atopix Therapeutics' Series A Round: